...
首页> 外文期刊>Drug delivery. >Ratiometric delivery of two therapeutic candidates with inherently dissimilar physicochemical property through pH-sensitive core–shell nanoparticles targeting the heterogeneous tumor cells of glioma
【24h】

Ratiometric delivery of two therapeutic candidates with inherently dissimilar physicochemical property through pH-sensitive core–shell nanoparticles targeting the heterogeneous tumor cells of glioma

机译:通过针对胶质瘤异质性肿瘤细胞的pH敏感的核壳纳米粒子,按比例输送两种具有固有不同的理化性质的治疗药物

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Abstract Currently, combination drug therapy is one of the most effective approaches to glioma treatment. However, due to the inherent dissimilar pharmacokinetics of individual drugs and blood brain barriers, it was difficult for the concomitant drugs to simultaneously be delivered to glioma in an optimal dose ratio manner. Herein, a cationic micellar core (Cur-M) was first prepared from d -α-tocopherol-grafted-ε-polylysine polymer to encapsulate the hydrophobic curcumin, followed by dopamine-modified-poly-γ-glutamic acid polymer further deposited on its surface as a anion shell through pH-sensitive linkage to encapsulate the hydrophilic doxorubicin (DOX) hydrochloride. By controlling the combinational Cur/DOX molar ratio at 3:1, a pH-sensitive core–shell nanoparticle (PDCP-NP) was constructed to simultaneously target the cancer stem cells (CSCs) and the differentiated tumor cells. PDCP-NP exhibited a dynamic diameter of 160.8?nm and a zeta-potential of –30.5?mV, while its core–shell structure was further confirmed by XPS and TEM. The ratiometric delivery capability of PDCP-NP was confirmed by in vitro and in vivo studies, in comparison with the cocktail Cur/DOX solution. Meanwhile, the percentage of CSCs in tumors was significantly decreased from 4.16% to 0.95% after treatment with PDCP-NP. Overall, PDCP-NP may be a promising carrier for the combination therapy with drug candidates having dissimilar physicochemical properties.
机译:摘要目前,联合药物治疗是治疗神经胶质瘤最有效的方法之一。然而,由于各个药物固有的药代动力学和血脑屏障不同,因此难以以最佳的剂量比方式将伴随的药物同时递送至神经胶质瘤。在此,首先从d-α-生育酚接枝的ε-聚赖氨酸聚合物制备阳离子胶束核(Cur-M),以包封疏水性姜黄素,然后将多巴胺改性的聚-γ-谷氨酸聚合物进一步沉积在其上表面作为阴离子壳,通过pH敏感键包裹亲水性阿霉素(DOX)盐酸盐。通过将Cur / DOX组合摩尔比控制为3:1,可以构建pH敏感的核壳纳米粒子(PDCP-NP),以同时靶向癌症干细胞(CSCs)和分化的肿瘤细胞。 PDCP-NP的动态直径为160.8?nm,ζ电位为–30.5?mV,而XPS和TEM进一步证实了其核壳结构。与鸡尾酒Cur / DOX溶液相比,PDCP-NP的比例传递能力已通过体外和体内研究得到证实。同时,用PDCP-NP治疗后,肿瘤中CSCs的百分比从4.16%显着降低至0.95%。总体而言,PDCP-NP可能是与具有不同理化特性的候选药物联合治疗的有希望的载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号